2025 Global Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report
Description
The 2025 Global Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy (CGT) Manufacturing Services Market globally are Lonza Group, Thermo Fisher Scientific, Catalent Inc., and WuXi Advanced Therapies. Lonza leads with a 14-17% market share, expanding viral vector capabilities and commercial production of allogeneic cell therapies using automation for scalable delivery. Thermo Fisher holds an 11-14% share, focusing on high-purity T-cell separation technology and modular closed systems for viral vector production to reduce contamination and ensure reliability. Catalent, with 9-12%, has enhanced GMP-grade plasmid DNA production and turnkey manufacturing services tailored for rare diseases. WuXi Advanced Therapies, at 7-10%, boosts viral vector production and uses AI-driven digital twin systems to optimize processes and reduce variability .
Fujifilm Diosynth Biotechnologies also plays a significant role with 6-9% market share, pioneering modular bioreactor suites and cryopreservation for autologous cell therapies. These companies emphasize flexible, scalable manufacturing infrastructure and regulatory compliance to meet global CGT demand. Collectively, they support clinical and commercial CGT development, enabling advanced therapy access worldwide via innovations in process automation, quality control, and integrated manufacturing services across multiple regions such as North America, Europe, and Asia .
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy (CGT) Manufacturing Services Market globally are Lonza Group, Thermo Fisher Scientific, Catalent Inc., and WuXi Advanced Therapies. Lonza leads with a 14-17% market share, expanding viral vector capabilities and commercial production of allogeneic cell therapies using automation for scalable delivery. Thermo Fisher holds an 11-14% share, focusing on high-purity T-cell separation technology and modular closed systems for viral vector production to reduce contamination and ensure reliability. Catalent, with 9-12%, has enhanced GMP-grade plasmid DNA production and turnkey manufacturing services tailored for rare diseases. WuXi Advanced Therapies, at 7-10%, boosts viral vector production and uses AI-driven digital twin systems to optimize processes and reduce variability .
Fujifilm Diosynth Biotechnologies also plays a significant role with 6-9% market share, pioneering modular bioreactor suites and cryopreservation for autologous cell therapies. These companies emphasize flexible, scalable manufacturing infrastructure and regulatory compliance to meet global CGT demand. Collectively, they support clinical and commercial CGT development, enabling advanced therapy access worldwide via innovations in process automation, quality control, and integrated manufacturing services across multiple regions such as North America, Europe, and Asia .
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
